BBOT Posts $56.5M Q2 Loss, Extends Cash Runway into 2028, and Advances KRAS Pipeline
BBOT sits 31% above its 52-week low of $7.
Summary
BBOT's Q2 loss widened to $56.5M on higher R&D spending, but $344.1M in cash provides runway into 2028. Clinical progress includes new combination dosing for its KRAS inhibitors.
Key Events · Earnings and Guidance · BBOT
-
Q2 Net Loss Widens to $56.5M
Net loss of $56.5M vs. $28.4M in Q2 2025, driven by R&D expenses of $49.2M (up from $27.4M) and G&A of $11.0M (up from $2.7M).
-
Cash Runway Extended into 2028
Cash, equivalents, and marketable securities totaled $344.1M at June 30, 2026, expected to fund operations into 2028.
-
Clinical Pipeline Advances
Initiated BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combinations; continued enrollment in BBO-8520 + pembrolizumab and BBO-8520 + BBO-10203 cohorts.
-
Preclinical Data Presented at AACR
Data highlighted BBO-11818 potency in KRAS G12D/V models and BBO-10203 efficacy in combination with HER2 inhibitors in HER2amp models.
Analysis · BBOT · Life Sciences
BridgeBio Oncology Therapeutics posted a wider Q2 loss of $56.5 million, driven by a near-doubling of R&D spend to $49.2 million as it advances three clinical-stage KRAS/PI3Kα programs. The company initiated two new combination cohorts — BBO-11818 with cetuximab and with BBO-10203 — and presented preclinical data at AACR. With $344.1 million in cash, management expects runway into 2028, removing near-term financing risk. The burn rate is high, but the pipeline progress and extended cash horizon are the key takeaways.
At the time of this filing, BBOT was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737M. The 52-week trading range was $7.00 to $14.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.